Respiratory Medicine Practice Questions

Q: A 56-year-old man presents with progressive dyspnea and chest tightness. He works in coal mining. Chest X-ray shows bilateral upper lobe nodules. What is the most likely diagnosis?

Coal worker's pneumoconiosis. ***Coal worker's pneumoconiosis***- This diagnosis is strongly supported by the patient's occupational exposure to **coal dust** and the progressive respiratory symptoms like **dyspnea** and **chest tightness**.- The characteristic Chest X-ray finding of bilateral, often small, **pulmonary nodules** predominantly located in the **upper lung zones** is classic for this condition.*Lung cancer*- Although coal miners have an increased risk of lung cancer, the presentation of diffuse **bilateral small nodules** is more typical of a pneumoconiosis than primary malignancy.- Lung cancer usually manifests as a single, dominant mass, or less commonly as reticulonodular interstitial disease, not typically as diffuse, symmetrical small nodules.*Silicosis*- Silicosis is caused by the inhalation of **crystalline silica** dust, prevalent in occupations like sandblasting or quarrying, which differs from pure coal mining exposure.- While silicosis also causes upper lobe nodules, it often presents radiologically with **"eggshell" calcification** of the hilar lymph nodes, a finding not specified in this case.*Tuberculosis*- Although **post-primary TB** targets the upper lobes, generalized diffuse nodularity suggests pneumoconiosis rather than a primary mycobacterial infection.- TB typically presents with systemic symptoms like **fever**, **night sweats**, and **weight loss**, which are not mentioned in this patient's presentation.*Sarcoidosis*- Sarcoidosis is a systemic disease of unknown etiology characterized by **non-caseating granulomas** and classically presents with **bilateral hilar lymphadenopathy (BHL)** on chest imaging.- The strong history of **coal mining** is the key factor favoring an occupational lung disease over sarcoidosis, as BHL is also absent.

Q: A 56-year-old man presents with progressive dyspnea and dry cough. HRCT shows bilateral lower lobe fibrosis with honeycombing. He has clubbing and restrictive spirometry. What medication may slow disease progression?

Pirfenidone. ***Pirfenidone***- The clinical presentation with progressive dyspnea, dry cough, clubbing, restrictive spirometry, and HRCT showing bilateral lower lobe fibrosis with **honeycombing** is highly characteristic of **Idiopathic Pulmonary Fibrosis (IPF)**.- **Pirfenidone** is an **anti-fibrotic** agent, along with nintedanib, approved for the treatment of mild to moderate IPF to slow disease progression by reducing the decline in **Forced Vital Capacity (FVC)**.*Prednisolone*- Systemic corticosteroids like **Prednisolone** are not recommended as monotherapy for **Idiopathic Pulmonary Fibrosis (IPF)** due to lack of proven long-term efficacy and potential harm.- They are primarily indicated for inflammatory interstitial lung diseases, such as those associated with **connective tissue diseases**, or for **acute exacerbations** of IPF.*Azathioprine*- **Azathioprine** is an immunosuppressant that was shown to be ineffective and potentially harmful in a triple-drug regimen for IPF in the **PANTHER-IPF trial**.- Immunosuppression is generally avoided in **Idiopathic Pulmonary Fibrosis** unless there is a strong suspicion of an alternative, inflammatory interstitial lung disease.*Cyclophosphamide*- **Cyclophosphamide** is a potent cytotoxic immunosuppressant typically reserved for severe, rapidly progressive forms of **connective tissue disease-associated ILD** (e.g., scleroderma-associated ILD or vasculitis).- It is not indicated for the primary management of **Idiopathic Pulmonary Fibrosis**, which is characterized by relentless fibrosis rather than a primary inflammatory process responsive to this therapy.*N-acetylcysteine*- Although previously studied for its antioxidant properties, the **PANTHER-IPF trial** demonstrated that **N-acetylcysteine** offered no benefit in slowing the progression of IPF and is no longer recommended.- Its primary clinical uses are as a mucolytic agent and as an antidote for **acetaminophen overdose**.

Q: A 54-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 1.8L (60% predicted), FEV1/FVC 0.55. He has a 40 pack-year smoking history. What is the most important intervention?

Smoking cessation. ***Smoking cessation***- This is the **single most important intervention** for patients with **COPD** who smoke, as it is the only measure proven to slow the rate of **FEV1 decline** and disease progression.- Quitting smoking significantly reduces symptoms, exacerbations, and mortality, directly addressing the primary etiological factor in this patient's 40 pack-year history.*Bronchodilators*- **Bronchodilators** (e.g., beta-agonists, anticholinergics) provide crucial **symptomatic relief** by improving airflow and reducing dyspnea, but they do not alter the natural history of COPD or stop the underlying disease progression.- They are essential for managing symptoms but are not the **most important intervention** to halt the destruction caused by smoking.*Inhaled corticosteroids*- **Inhaled corticosteroids (ICS)** are typically indicated for patients with more severe COPD (e.g., FEV1 < 50% predicted) and a history of **frequent exacerbations**, often in combination with long-acting bronchodilators.- While they can reduce inflammation and exacerbation rates, ICS do not reverse or prevent the progressive lung damage caused by smoking.*Pulmonary rehabilitation*- **Pulmonary rehabilitation** is a highly effective intervention that improves **exercise capacity**, reduces dyspnea, and enhances quality of life in patients with COPD.- However, it does not modify the underlying **disease progression** or stop the decline in lung function, which is the primary benefit of smoking cessation.*Long-term oxygen therapy*- **Long-term oxygen therapy (LTOT)** is indicated for patients with **severe chronic hypoxemia** (PaO2 < 55 mmHg or SaO2 < 88%) to improve survival and quality of life.- This intervention addresses a consequence of advanced COPD but does not directly prevent or slow the progression of the disease itself, which is the focus of the question.

Q: A 58-year-old man presents with progressive dyspnea and fatigue. Chest X-ray shows bilateral lower lobe shadowing. HRCT shows honeycombing and traction bronchiectasis. He has finger clubbing. What is the prognosis?

Poor with median survival 2-5 years. ***Poor with median survival 2-5 years***- The progressive dyspnea, fatigue, finger clubbing, and HRCT findings of **honeycombing** and **traction bronchiectasis** are classic features of **Idiopathic Pulmonary Fibrosis (IPF)**.- IPF is a relentlessly progressive lung disease with a **poor prognosis**, typically having a median survival of **2 to 5 years** from diagnosis without lung transplantation.*Excellent with treatment*- IPF is an **irreversible, progressive fibrotic lung disease** for which there is currently no curative medical treatment, precluding an excellent prognosis.- Although anti-fibrotic medications can slow the rate of decline, they do not halt or reverse the underlying **pulmonary fibrosis**.*Good with early intervention*- Despite early diagnosis and intervention with anti-fibrotic drugs, the established **Usual Interstitial Pneumonia (UIP)** pattern of IPF implies a rapid and unfavorable progression.- Patients with IPF remain at high risk of **acute exacerbations** and progressive **respiratory failure**, even with timely management.*Variable depending on cause*- The classic presentation of progressive dyspnea, clubbing, and a definable **UIP pattern** on HRCT points strongly to **Idiopathic Pulmonary Fibrosis**, which has a consistently unfavorable prognosis.- Prognostic variability is more often associated with other Interstitial Lung Diseases (ILDs) like non-specific interstitial pneumonia (**NSIP**), not IPF.*Benign condition*- IPF is far from benign; it is a serious, ultimately **fatal condition** characterized by continuous and irreversible destruction of lung architecture.- The presence of **traction bronchiectasis** and **honeycombing** signifies advanced, non-reversible scarring and distortion of lung tissue, indicating a severe disease.

Q: A 54-year-old man presents with progressive dyspnea and bilateral lower lobe crackles. Chest X-ray shows bilateral infiltrates. He works in shipbuilding. What is the most likely diagnosis?

Asbestosis. ***Asbestosis***- The patient's history of working in **shipbuilding** is a classic exposure for **asbestos** fibers.- Asbestosis typically causes **interstitial pulmonary fibrosis**, preferentially affecting the **lower lobes**, leading to progressive dyspnea and **bibasilar crackles**. *COPD*- This involves **obstructive lung disease** (e.g., chronic bronchitis or emphysema) characterized by airflow limitation, not the restrictive pattern suggested by crackles and infiltrates.- CXR typically shows signs of **hyperinflation** or large bullae, rather than diffuse bilateral interstitial infiltrates.*Silicosis*- Silicosis is caused by inhaling **free crystalline silica** (e.g., mining, quarrying, sandblasting), an exposure typically unrelated to shipbuilding.- Radiographically, silicosis usually presents with **nodular opacities**, classically affecting the **upper lobes**.*Coal worker's pneumoconiosis*- This condition is due to the inhalation of **coal dust**, almost exclusively seen in **coal miners**.- Simple CWP generally causes small **nodular opacities**, also predominantly in the **upper lung fields**.*Hypersensitivity pneumonitis*- Caused by immunologic reactions to inhaled **organic antigens** (e.g., bird droppings, mold from farmers' lung), not asbestos exposure.- HP often presents with systemic symptoms, and the pathology involves the **alveolar walls** and terminal bronchioles, lacking the specific pleural/parenchymal changes linked to asbestos.

Question 1

A 56-year-old man presents with progressive dyspnea and chest tightness. He works in coal mining. Chest X-ray shows bilateral upper lobe nodules. What is the most likely diagnosis?

Accepted Answer

Coal worker's pneumoconiosis

Answer

Lung cancer

Answer

Silicosis

Answer

Tuberculosis

Answer

Sarcoidosis

Question 2

A 56-year-old man presents with progressive dyspnea and dry cough. HRCT shows bilateral lower lobe fibrosis with honeycombing. He has clubbing and restrictive spirometry. What medication may slow disease progression?

Accepted Answer

Pirfenidone

Answer

Prednisolone

Answer

Azathioprine

Answer

Cyclophosphamide

Answer

N-acetylcysteine

Question 3

A 54-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 1.8L (60% predicted), FEV1/FVC 0.55. He has a 40 pack-year smoking history. What is the most important intervention?

Accepted Answer

Smoking cessation

Answer

Bronchodilators

Answer

Inhaled corticosteroids

Answer

Pulmonary rehabilitation

Answer

Long-term oxygen therapy

Question 4

A 58-year-old man presents with progressive dyspnea and fatigue. Chest X-ray shows bilateral lower lobe shadowing. HRCT shows honeycombing and traction bronchiectasis. He has finger clubbing. What is the prognosis?

Accepted Answer

Poor with median survival 2-5 years

Answer

Excellent with treatment

Answer

Good with early intervention

Answer

Variable depending on cause

Answer

Benign condition

Question 5

A 54-year-old man presents with progressive dyspnea and bilateral lower lobe crackles. Chest X-ray shows bilateral infiltrates. He works in shipbuilding. What is the most likely diagnosis?

Accepted Answer

Asbestosis

Answer

COPD

Answer

Silicosis

Answer

Coal worker's pneumoconiosis

Answer

Hypersensitivity pneumonitis

Respiratory Medicine — MCQs

Respiratory Medicine — MCQs

On this page

Practice by Chapter

Want unlimited practice?